. 2021 Dec 6;49(12):03000605211062442. doi: 10.1177/03000605211062442

Table 1.

Relationship between patient characteristics and ALI.

	Baseline	ALI < 41.20	ALI ≥ 41.20	P value
	Baseline	n=125	n=214	P value
Age				0.460
	<65 years	84	152
	≥65 years	41	62
Sex				<0.001
	Male	81	86
	Female	44	128
Pathology				0.167
	Adenocarcinoma	113	202
	Squamous cell carcinoma	12	12
Death				<0.001
	Yes	32	22
	No	93	192
Stage				0.045
	0	28	58
	IA	54	112
	IB-II	22	24
	IIIA	21	20
Surgical Procedure				0.104
	Wedge resection	57	111
	Segmentectomy	28	57
	Lobectomy	40	46
Smoking				0.012
	Never	74	155
	Current/ever	51	59
BMI				0.015
	<18.5	5	3
	≥18.5 to <24	71	95
	≥24	49	116
Recurrence				0.001
	Yes	21	12
	No	104	202
PS				0.585
	0–1	99	164
	≥2	26	50
CCI				0.222
	0–1	61	98
	2–3	13	13
	≥4	51	103
Postoperative Treatment				0.520
	Yes	26	51
	No	99	163
CRP (mg/L)				0.270
	<0.05	1	2
	≥0.05	56	114
WBC (×10⁹/L)				0.619
	<5.63	66	107
	≥5.63	59	107
RBC (×10¹²/L)				0.320
	<5.11	107	191
	≥5.11	18	23
NEUT (×10⁹/L)				0.079
	<3.12	54	72
	≥3.12	71	142
LYMPH (×10⁹/L)				0.540
	<2.47	112	196
	≥2.47	13	18
HGB (g/L)				0.225
	<151.50	96	176
	≥151.50	29	38
PLT (×10⁹/L)				0.148
	<459	124	207
	≥459	1	7
MONO (×10⁹/L)				0.029
	<0.57	125	206
	≥0.57	0	8
EO (×10⁹/L)				0.934
	<0.11	80	136
	≥0.11	45	78
BASO (×10⁹/L)				0.056
	<0.08	120	212
	≥0.08	5	2
MCV (fL)				0.973
	<90.55	31	47
	≥90.55	30	46
RDW (%)				0.262
	<11.65	2	7
	≥11.65	60	86
ALB (g/dL)				0.385
	<4.24	46	89
	≥4.24	79	125
LDH (U/L)				0.901
	<187.25	89	151
	≥187.25	36	63
CEA (ng/mL)				0.759
	<4.21	80	133
	≥4.21	18	27
NSE (ng/mL)				0.624
	<10.18	22	40
	≥10.18	59	92
CYFRA21-1 (ng/mL)				0.197
	<3.56	69	103
	≥3.56	13	31
SCC (ng/mL)				0.391
	<0.69	15	18
	≥0.69	71	118
NLR				0.265
	<1.89	52	76
	≥1.89	73	138
LMR				0.048
	<3.74	10	33
	≥3.74	115	151
PLR				0.758
	<87.26	11	21
	≥87.26	114	193

Note: The number of deaths in the death group is the total number of deaths and loss to follow-up.

ALI, advanced lung cancer inflammation index; BMI, body mass index; PS, performance status; CCI, Charlson comorbidity index; CRP, C-reactive protein; WBC, white blood cell; RBC, red blood cell; NEUT, Neutrophil; LYMPH, Lymphocyte; HGB, hemoglobin; PLT, platelet; MONO, monocyte; EO, eosinophil; BASO, basophil; MCV, mean corpuscular volume; RDW, red cell distribution width; ALB, albumin; LDH, lactate dehydrogenase; CEA, carcinoembryonic antigen; NSE, neuron specific enolase; CYFRA 21-1, cytokeratin-19 fragment; SCC, squamous cell carcinoma antigen; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PLR, platelet to lymphocyte ratio.